Inhibition of fatty acid synthesis induces differentiation and reduces tumor burden in childhood neuroblastoma
María Victoria Ruiz-Pérez,
Lourdes Sainero-Alcolado,
Ganna Oliynyk,
Isabell Matuschek,
Nicola Balboni,
S.J. Kumari A. Ubhayasekera,
Marteinn Thor Snaebjornsson,
Kamil Makowski,
Kristina Aaltonen,
Daniel Bexell,
Dolors Serra,
Roland Nilsson,
Jonas Bergquist,
Almut Schulze,
Marie Arsenian-Henriksson
Affiliations
María Victoria Ruiz-Pérez
Department of Microbiology, Tumor and Cell Biology (MTC), Biomedicum B7, Karolinska Institutet, 171 65 Stockholm, Sweden; Corresponding author
Lourdes Sainero-Alcolado
Department of Microbiology, Tumor and Cell Biology (MTC), Biomedicum B7, Karolinska Institutet, 171 65 Stockholm, Sweden
Ganna Oliynyk
Department of Microbiology, Tumor and Cell Biology (MTC), Biomedicum B7, Karolinska Institutet, 171 65 Stockholm, Sweden
Isabell Matuschek
Department of Microbiology, Tumor and Cell Biology (MTC), Biomedicum B7, Karolinska Institutet, 171 65 Stockholm, Sweden
Nicola Balboni
Department of Microbiology, Tumor and Cell Biology (MTC), Biomedicum B7, Karolinska Institutet, 171 65 Stockholm, Sweden
S.J. Kumari A. Ubhayasekera
Analytical Chemistry, Department of Chemistry and Science for Life Laboratory, Uppsala University, 751 24 Uppsala, Sweden
Marteinn Thor Snaebjornsson
Tumor Metabolism and Microenvironment, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
Kamil Makowski
Department of Inorganic and Organic Chemistry, Section of Organic Chemistry, Faculty of Chemistry, University of Barcelona, 08028 Barcelona, Spain
Kristina Aaltonen
Translational Cancer Research, Lund University, 22381 Lund, Sweden
Daniel Bexell
Translational Cancer Research, Lund University, 22381 Lund, Sweden
Dolors Serra
Department of Biochemistry and Physiology, School of Pharmacy, Institute of Biomedicine of the University of Barcelona (IBUB), University of Barcelona, 08028 Barcelona, Spain, and CIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain
Roland Nilsson
Cardiovascular Medicine Unit, Department of Medicine, Karolinska Institutet, 17176 Stockholm, Sweden; Division of Cardiovascular Medicine, Karolinska University Hospital, 17176 Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institutet, 17176 Stockholm, Sweden
Jonas Bergquist
Analytical Chemistry, Department of Chemistry and Science for Life Laboratory, Uppsala University, 751 24 Uppsala, Sweden
Almut Schulze
Tumor Metabolism and Microenvironment, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
Marie Arsenian-Henriksson
Department of Microbiology, Tumor and Cell Biology (MTC), Biomedicum B7, Karolinska Institutet, 171 65 Stockholm, Sweden; Corresponding author
Summary: Many metabolic pathways, including lipid metabolism, are rewired in tumors to support energy and biomass production and to allow adaptation to stressful environments. Neuroblastoma is the second deadliest solid tumor in children. Genetic aberrations, as the amplification of the MYCN-oncogene, correlate strongly with disease progression. Yet, there are only a few molecular targets successfully exploited in the clinic. Here we show that inhibition of fatty acid synthesis led to increased neural differentiation and reduced tumor burden in neuroblastoma xenograft experiments independently of MYCN-status. This was accompanied by reduced levels of the MYCN or c-MYC oncoproteins and activation of ERK signaling. Importantly, the expression levels of genes involved in de novo fatty acid synthesis showed prognostic value for neuroblastoma patients. Our findings demonstrate that inhibition of de novo fatty acid synthesis is a promising pharmacological intervention strategy for the treatment of neuroblastoma independently of MYCN-status.